Biogen Idec and Cardiokine Partner to Develop Lixivaptan, a Novel Vasopressin Antagonist
Lixivaptan to enter Phase III clinical trial in 2007 in heart failure patients
05-Jul-2007 -
Biogen Idec and Cardiokine, Inc., a privately-held specialty pharmaceutical company focused on the development of drugs for the treatment of heart failure and related indications, announced the signing of an agreement to jointly develop lixivaptan, an oral compound expected to enter a Phase III ...
Biogen Idec
cirrhosis
clinical trials
+6